ライフサイエンスコーパス: angiotensin-converting enzyme 2

1 transgenic for the SARS-CoV receptor (human angiotensin-converting enzyme 2).

2 soluble forms of the receptor for the virus, angiotensin converting enzyme 2.

3 red by binding of the viral spike protein to angiotensin-converting enzyme 2.

4 n system, angiotensin-converting enzyme, and angiotensin-converting enzyme 2.

5 hin its trimeric spike glycoprotein to human angiotensin-converting enzyme 2.

6 tibodies with greater than 90% inhibition of angiotensin-converting enzyme 2.

7 a to inhibit the binding of spike protein to angiotensin-converting enzyme 2.

8 ion of the functional receptor of the virus, angiotensin-converting enzyme 2.

9 ngiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2.

10 y be associated with whether the virus binds angiotensin-converting enzyme-2.

11 ents infected by viruses that do not bind to angiotensin-converting enzyme-2.

12 e developed transgenic mice expressing human angiotensin-converting enzyme 2, a functional receptor f

13 Background Angiotensin-converting enzyme 2, a target of severe acut

14 Due to differences in human and murine angiotensin converting enzyme 2 (ACE-2) receptor, initia

15 The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor

16 A glass bottom plate coated with angiotensin-converting enzyme 2 (ACE-2) protein imitates

17 Angiotensin-converting enzyme 2 (ACE-2), neprilysin (NEP

18 tudies revealed a preferential expression of angiotensin-converting enzyme 2 (ACE-2), the functional

19 an eightfold affinity increase towards human angiotensin-converting enzyme-2 (ACE-2).

20 virginianus), an animal species in which the angiotensin converting enzyme 2 (ACE2) - the SARS-CoV-2

21 An angiotensin converting enzyme 2 (ACE2) decoy that compet

22 protein to bind to the cell surface receptor angiotensin converting enzyme 2 (ACE2) glycoprotein and

23 Angiotensin converting enzyme 2 (ACE2) is a key regulato

24 Angiotensin converting enzyme 2 (ACE2) is a negative reg

25 Angiotensin converting enzyme 2 (ACE2) is an enzyme that

26 ion occurs through binding of the virus with angiotensin converting enzyme 2 (ACE2) on the cell membr

27 Angiotensin converting enzyme 2 (ACE2) plays an importan

28 Accumulating evidence suggests that Angiotensin Converting Enzyme 2 (ACE2) possesses the abi

29 pends on the binding of its Spike protein to angiotensin converting enzyme 2 (ACE2) presented on host

30 and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affin

31 ficiently at low levels of cellular receptor angiotensin converting enzyme 2 (ACE2), and its pseudoty

32 Angiotensin converting enzyme 2 (ACE2), the host recepto

33 Angiotensin converting enzyme 2 (ACE2), the receptor for

34 moke causes a dose-dependent upregulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 r

35 Recently, a new member of the RAS, angiotensin converting enzyme 2 (ACE2), was discovered.

36 e, we developed the metallo-enzyme domain of angiotensin converting enzyme 2 (ACE2)-the cellular rece

37 ns of SARS-S with the receptor for SARS-CoV, angiotensin converting enzyme 2 (ACE2); (ii) SSAA09E1 {[

38 2, the pathogenic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry

39 Angiotensin-converting enzyme 2 (ACE2 or ACEH) is a nove

40 n in the short peptide epitope EDLFYQ of the angiotensin-converting enzyme 2 (ACE2) alpha1 helix doma

41 Angiotensin-converting enzyme 2 (ACE2) and accessory pro

42 main (RBD) showing crucial interactions with angiotensin-converting enzyme 2 (ACE2) and cross-reactin

43 ELVs downregulate angiotensin-converting enzyme 2 (ACE2) and enhance the e

44 Angiotensin-converting enzyme 2 (ACE2) and its product,

45 upted RBD engagement with the human receptor angiotensin-converting enzyme 2 (ACE2) and potently neut

46 ndrome coronavirus 2 (SARS-CoV-2) infection, angiotensin-converting enzyme 2 (ACE2) and transmembrane

47 ausing COVID-19, is facilitated by host cell angiotensin-converting enzyme 2 (ACE2) and transmembrane

48 s critical for SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane

49 SARS-CoV-2 and the human cellular receptor, angiotensin-converting enzyme 2 (ACE2) are both densely

50 al populations in the distal lung expressing Angiotensin-converting enzyme 2 (ACE2) are infrequent, a

51 ID-19 is a highly contagious virus that uses Angiotensin-converting enzyme 2 (ACE2) as a receptor to

52 SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) as its receptor t

53 is the only group I coronavirus known to use angiotensin-converting enzyme 2 (ACE2) as its receptor.

54 Early evidence pointed to angiotensin-converting enzyme 2 (ACE2) as SARS-CoV-2 ent

55 The virus utilizes angiotensin-converting enzyme 2 (ACE2) as the primary re

56 how that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and th

57 a trimeric spike surface protein, a dimeric angiotensin-converting enzyme 2 (ACE2) cell-surface rece

58 ke receptor-binding domain (RBD) antibodies, angiotensin-converting enzyme 2 (ACE2) competition, and

59 In HAE cell cultures, angiotensin-converting enzyme 2 (ACE2) expression govern

60 Angiotensin-converting enzyme 2 (ACE2) expression has be

61 Elevated angiotensin-converting enzyme 2 (ACE2) expression in org

62 ity RNA in situ mapping revealed the highest angiotensin-converting enzyme 2 (ACE2) expression in the

63 coronaviruses to utilize animal orthologs of angiotensin-converting enzyme 2 (ACE2) for cell entry.

64 SARS-CoV-2), which causes COVID-19, utilizes angiotensin-converting enzyme 2 (ACE2) for entry into ta

65 the ligand and key binding-site residues of angiotensin-converting enzyme 2 (ACE2) from its homologu

66 This study compares angiotensin-converting enzyme 2 (ACE2) gene expression,

67 Angiotensin-converting enzyme 2 (ACE2) has been identifi

68 Angiotensin-converting enzyme 2 (ACE2) has been identifi

69 Angiotensin-converting enzyme 2 (ACE2) has emerged as a

70 Angiotensin-converting enzyme 2 (ACE2) immobilized on th

71 locked S conformation, resulting in reduced angiotensin-converting enzyme 2 (ACE2) interaction in vi

72 Angiotensin-converting enzyme 2 (ACE2) is a cellular rec

73 Human angiotensin-converting enzyme 2 (ACE2) is a functional r

74 Angiotensin-converting enzyme 2 (ACE2) is a functional r

75 Angiotensin-converting enzyme 2 (ACE2) is a metalloprote

76 Angiotensin-converting enzyme 2 (ACE2) is a potent negat

77 Angiotensin-converting enzyme 2 (ACE2) is a receptor for

78 Angiotensin-converting enzyme 2 (ACE2) is an entry recep

79 Angiotensin-converting enzyme 2 (ACE2) is an entry recep

80 The membrane-associated carboxypeptidase angiotensin-converting enzyme 2 (ACE2) is an essential r

81 Angiotensin-converting enzyme 2 (ACE2) is an integral me

82 SARS-CoV-2 spike protein binding to angiotensin-converting enzyme 2 (ACE2) is critical for v

83 Although angiotensin-converting enzyme 2 (ACE2) is crucial for SA

84 In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated i

85 Angiotensin-converting enzyme 2 (ACE2) is the canonical

86 Angiotensin-converting enzyme 2 (ACE2) is the cell-entry

87 Angiotensin-converting enzyme 2 (ACE2) is the cell-surfa

88 Angiotensin-converting enzyme 2 (ACE2) is the main entry

89 2 (TMPRSS2) mRNA expression while decreasing angiotensin-converting enzyme 2 (ACE2) mRNA and protein

90 ent study showed that directed expression of angiotensin-converting enzyme 2 (ACE2) on cells previous

91 Because angiotensin-converting enzyme 2 (ACE2) on host cells ser

92 Because spike S1 of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) on host cells to

93 ry syndrome coronavirus 2 (SARS-CoV-2) binds angiotensin-converting enzyme 2 (ACE2) on host cells to

94 can efficiently bind to and use specific bat angiotensin-converting enzyme 2 (ACE2) orthologues and,

95 Angiotensin-converting enzyme 2 (ACE2) plays a fundament

96 as recently reported that the human receptor angiotensin-converting enzyme 2 (ACE2) plays a key role

97 case studies were demonstrated, one being on angiotensin-converting enzyme 2 (ACE2) protein which is

98 Engineered angiotensin-converting enzyme 2 (ACE2) proteins with aug

99 e novel coronavirus canonically utilizes the angiotensin-converting enzyme 2 (ACE2) receptor and the

100 RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a pre

101 ining region (CDR) H3, and competes with the angiotensin-converting enzyme 2 (ACE2) receptor because

102 All variants showed increased angiotensin-converting enzyme 2 (ACE2) receptor binding

103 arly transmission phase and increasing human angiotensin-converting enzyme 2 (ACE2) receptor binding

104 rotein), which binds with not only the human angiotensin-converting enzyme 2 (ACE2) receptor but also

105 However, while SARS-CoV uses the human angiotensin-converting enzyme 2 (ACE2) receptor for cell

106 SARS-CoV-2 spike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a sin

107 furthered our understanding of spike protein-angiotensin-converting enzyme 2 (ACE2) receptor interact

108 s 2 (SARS-CoV-2) spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor is a pro

109 n S likely increase recognition of the mouse angiotensin-converting enzyme 2 (ACE2) receptor not only

110 OCs had a greater affinity towards the human angiotensin-converting enzyme 2 (ACE2) receptor than tha

111 the spike protein of SARS-CoV-2 to the human angiotensin-converting enzyme 2 (ACE2) receptor triggers

112 tible host species based on variation in the angiotensin-converting enzyme 2 (ACE2) receptor used for

113 domain (RBD), the hexapeptide YKYRYL on the angiotensin-converting enzyme 2 (ACE2) receptor, and its

114 were engineered to stably express the human angiotensin-converting enzyme 2 (ACE2) receptor, but sta

115 By interacting with the human angiotensin-converting enzyme 2 (ACE2) receptor, the spi

116 oprotein (S400-600), which overlaps with the angiotensin-converting enzyme 2 (ACE2) receptor-binding

117 Antibodies that target the angiotensin-converting enzyme 2 (ACE2) receptor-binding

118 hile maintaining high affinity for the human angiotensin-converting enzyme 2 (ACE2) receptor.

119 V-2 spike glycoprotein (S-protein) and human angiotensin-converting enzyme 2 (ACE2) receptor.

120 ceptor-binding domain (RBD) of SARS-CoV-2 to angiotensin-converting enzyme 2 (ACE2) receptor.

121 action of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor.

122 use of species-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors.

123 Angiotensin-converting enzyme 2 (ACE2) serves protective

124 ycoprotein receptor binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) stand in as proxi

125 stantially higher affinity for host receptor angiotensin-converting enzyme 2 (ACE2) than BA.5 and oth

126 racts with both cellular heparan sulfate and angiotensin-converting enzyme 2 (ACE2) through its recep

127 by adipocytes, can be catabolized by adipose angiotensin-converting enzyme 2 (ACE2) to form Ang(1-7).

128 ry syndrome (SARS-CoV) utilizes the receptor angiotensin-converting enzyme 2 (ACE2) to infect cells.

129 Infection of human angiotensin-converting enzyme 2 (ACE2) transgenic mice a

130 clade 3 sarbecovirus PRD-0038 S has a broad angiotensin-converting enzyme 2 (ACE2) usage and that re

131 -CoVs), while recent studies have identified angiotensin-converting enzyme 2 (ACE2) usage in multiple

132 Angiotensin-converting enzyme 2 (ACE2) was discovered 25

133 Angiotensin-converting enzyme 2 (ACE2) was identified as

134 evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affin

135 the mouse orthologue of the human receptor, angiotensin-converting enzyme 2 (ACE2)(4).

136 With the discovery of the angiotensin-converting enzyme 2 (ACE2), a protective axi

137 Angiotensin-converting enzyme 2 (ACE2), a recently ident

138 SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert w

139 l host binding via the cell surface receptor angiotensin-converting enzyme 2 (ACE2), as well as the s

140 mploy the same receptor for host cell entry, angiotensin-converting enzyme 2 (ACE2), but it is largel

141 2) virus enters host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or n

142 of the viral Spike protein to host receptor angiotensin-converting enzyme 2 (ACE2), followed by fusi

143 - SARS-CoV-2 - gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the

144 species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at d

145 d binding to the human cell-surface receptor angiotensin-converting enzyme 2 (ACE2), increased replic

146 re acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme 2 (ACE2), is highly expres

147 Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), isolated from SA

148 onavirus 2 (SARS-CoV-2) viral association to angiotensin-converting enzyme 2 (ACE2), its main host re

149 in is a candidate vaccine antigen that binds angiotensin-converting enzyme 2 (ACE2), leading to virus

150 S-CoV-2 for entry and replication, including angiotensin-converting enzyme 2 (ACE2), may disrupt SARS

151 However, angiotensin-converting enzyme 2 (ACE2), responsible for

152 Expression of the SARS-CoV receptor, angiotensin-converting enzyme 2 (ACE2), resulted in SARS

153 lity to infection by modifying expression of angiotensin-converting enzyme 2 (ACE2), the cell entry r

154 involved in SARS-CoV-2 infection, including angiotensin-converting enzyme 2 (ACE2), the receptor for

155 s, we demonstrate that, in addition to human angiotensin-converting enzyme 2 (ACE2), the Spike glycop

156 demic in 2002 and 2003, binds to a receptor, angiotensin-converting enzyme 2 (ACE2), through the rece

157 interface between the RBD and its receptor, angiotensin-converting enzyme 2 (ACE2), to assess their

158 eloped by tethering the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), to known non-neu

159 The receptor for SARS-CoV-2 binding, angiotensin-converting enzyme 2 (ACE2), was not detected

160 r-binding domain (RBD) and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate b

161 SARS-CoV spike protein and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate b

162 lar localization of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper

163 d 489) overlapping a critical portion of the angiotensin-converting enzyme 2 (ACE2)-binding surface.

164 .617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)-competing antibod

165 V-2 and SARS-CoV recognize the same receptor-angiotensin-converting enzyme 2 (ACE2)-in humans(3,4).

166 he scarcity of the SARS-CoV-2 receptor-human angiotensin-converting enzyme 2 (ACE2)-in the respirator

167 izes an epitope that partially overlaps with angiotensin-converting enzyme 2 (ACE2)-interacting sites

168 ternative receptor for SARS-CoV-2 entry into angiotensin-converting enzyme 2 (ACE2)-negative cells. S

169 In this study, we developed angiotensin-converting enzyme 2 (ACE2)-specific, peptide

170 gaining binding affinity for human receptor angiotensin-converting enzyme 2 (ACE2).

171 acute respiratory syndrome CoV (SARS) CoV is angiotensin-converting enzyme 2 (ACE2).

172 a viral spike protein and its host receptor, angiotensin-converting enzyme 2 (ACE2).

173 ost cell infection is mediated by binding to angiotensin-converting enzyme 2 (ACE2).

174 attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2).

175 the S glycoprotein and the cellular receptor angiotensin-converting enzyme 2 (ACE2).

176 n and those expressing the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2).

177 (SARS) infects cells expressing the receptor angiotensin-converting enzyme 2 (ACE2).

178 domain and the binding affinity for receptor angiotensin-converting enzyme 2 (ACE2).

179 of the viral Spike protein and the cellular angiotensin-converting enzyme 2 (ACE2).

180 the binding site for the cellular receptor, angiotensin-converting enzyme 2 (ACE2).

181 ny, of the canonical receptor of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2).

182 nding to the cellular receptor of the virus, angiotensin-converting enzyme 2 (ACE2).

183 e binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2).

184 protein (S(RBD)) from interacting with human angiotensin-converting enzyme 2 (ACE2).

185 19 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).

186 its Spike protein and the host cell receptor angiotensin-converting enzyme 2 (ACE2).

187 SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2).

188 ive arm of the renin angiotensin system, the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)

189 ment of the antibody to block RBD binding to angiotensin-converting enzyme 2 (ACE2; hereafter referre

190 ment of the antibody to block RBD binding to angiotensin-converting enzyme 2 (ACE2; hereafter referre

191 nt parameters to identify factors related to angiotensin-converting enzyme-2 (ACE2) expression within

192 Angiotensin-converting enzyme-2 (ACE2) is a critical reg

193 Angiotensin-converting enzyme-2 (ACE2) is a negative reg

194 In this paper, we report that angiotensin-converting enzyme-2 (ACE2) protected against

195 Angiotensin-converting enzyme-2 (ACE2) receptor-targetin

196 ssion of the SARS-CoV-2 viral entry receptor angiotensin-converting enzyme-2 (ACE2).

197 e receptor binding domain that engages human angiotensin-converting enzyme-2 (ACE2).

198 Angiotensin-converting-enzyme-2 (ACE2) has been describe

199 Human angiotensin-converting enzyme 2(ACE2) was identified as

200 No changes in bronchoalveolar lavage fluid angiotensin-converting enzyme 2 activity were found.

201 duced hyperuricaemia and increased levels of angiotensin-converting enzyme 2 and angiotensin (1-7).

202 The angiotensin-converting enzyme 2 and angiotensin-(1-7) (A

203 The conversion is catalyzed by angiotensin-converting enzyme 2 and other enzymes that s

204 domain (RBD) are compared with those between angiotensin-converting enzyme 2 and RBD complexes.

205 zed that trophoblasts at term do not express angiotensin-converting enzyme 2 and transmembrane protea

206 ACE2 (angiotensin-converting enzyme 2) and Ang 1-7 (angiotensi

207 ACE2 (angiotensin-converting enzyme 2) and NEP (neprilysin) in

208 us-specific capture agent (in this instance, angiotensin-converting enzyme 2), and finally quantifies

209 ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmemb

210 on with enhanced BP, decreased expression of angiotensin converting enzyme 2, and increased expressio

211 eptapeptide generated by catalytic action of angiotensin-converting enzyme-2 angiotensin A or directl

212 The counter-regulatory axis, Angiotensin Converting Enzyme 2, Angiotensin-(1-7), Mas

213 ) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas rec

214 is brief perspective, we examine the role of angiotensin converting enzyme 2 as the receptor for seve

215 han SARS-CoV according to computed S protein-angiotensin-converting enzyme 2 binding free energy chan

216 nity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and

217 ity by inhibition of receptor-binding domain-angiotensin-converting enzyme 2 binding.

218 protein with approximately 50% homology with angiotensin converting enzyme 2, but without a catalytic

219 BD, infected cells expressing human receptor angiotensin-converting enzyme 2, but with 90 to 95% less

220 rease in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respirat

221 Unlike angiotensin-converting enzyme 2, collectrin lacks any ca

222 Arteriolar angiotensin-converting enzyme 2 endothelial expression w

223 Background SARS-CoV-2 targets angiotensin-converting enzyme 2-expressing cells in the

224 part, could be attributable to a decrease in angiotensin-converting enzyme 2 expression observed in H

225 55 in oral cavity is predicted to upregulate angiotensin-converting enzyme 2 expression, essential SA

226 an alternate viral illness; (3) investigate angiotensin-converting enzyme 2 expression; and (4) prov

227 g their affinity for a viral receptor, human angiotensin-converting enzyme 2 (hACE-2), and their sens

228 Alpha, Beta, and Delta VoC in the K18 human angiotensin converting enzyme 2 (hACE2) transgenic mouse

229 at binds to its receptor glycoprotein, human angiotensin converting enzyme 2 (hACE2), and mediates vi

230 ding domain (RBD) binding its receptor human angiotensin converting enzyme 2 (hACE2).

231 virus attachment to its host receptor, human angiotensin converting enzyme-2 (hACE2).

232 ted coronavirus (SARS-CoV-2) that uses human angiotensin-converting enzyme 2 (hACE2) as the entry rec

233 e show that transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cyt

234 alidation, and optimization of de novo human angiotensin-converting enzyme 2 (hACE2) decoys to neutra

235 s the SARS-coronavirus entry receptor, human angiotensin-converting enzyme 2 (hACE2) driven by the ke

236 ed conformational capacity for binding human angiotensin-converting enzyme 2 (hACE2) for at least a w

237 ) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects

238 ne responses and better protection for human angiotensin-converting enzyme 2 (hACE2) transgenic mice

239 tion in HEK293T cells that overexpress human angiotensin-converting enzyme 2 (hACE2) without triggeri

240 complexed with their common receptor, human angiotensin-converting enzyme 2 (hACE2), and proposed th

241 In response to human receptor angiotensin-converting enzyme 2 (hACE2), S opens sequent

242 umented interaction with its receptor, human angiotensin-converting enzyme 2 (hACE2), SGP has been fo

243 d that transgenic (Tg) mice expressing human angiotensin-converting enzyme 2 (hACE2), the receptor fo

244 ed infection by selectively expressing human angiotensin-converting enzyme 2 (hACE2), the SARS-CoV-2

245 recognition via interactions with the human angiotensin-converting enzyme 2 (hACE2).

246 mouse orthologue of its human entry receptor angiotensin-converting enzyme 2 (hACE2).

247 a set of six human mAbs that bind the human angiotensin-converting enzyme-2 (hACE2) receptor, rather

248 ce that express the SARS-CoV receptor (human angiotensin-converting enzyme 2 [hACE2]) in airway and o

249 The role of angiotensin converting enzyme 2 has expanded from regula

250 An angiotensin-converting enzyme 2 immunohistochemical H-sc

251 essing a functional SARS-CoV receptor (human angiotensin-converting enzyme 2) in a dose-dependent man

252 n of Toll-like receptor ligands and an ACE2 (angiotensin-converting enzyme 2) inhibitor.

253 ose receptor binding domain (RBD) recognizes angiotensin-converting enzyme 2, initiating conformation

254 t cells by disrupting the spike glycoprotein-angiotensin-converting enzyme 2 interaction has already

255 racts at the periphery of the SARS-CoV-2 RBD-angiotensin-converting enzyme 2 interface.

256 r by adsorptive transcytosis and that murine angiotensin-converting enzyme 2 is involved in brain and

257 Angiotensin-converting enzyme 2 is the functional recept

258 In fact, ACE2 (angiotensin-converting-enzyme 2) is the pivotal receptor

259 was lower in fetal growth restriction in an angiotensin-converting enzyme 2 knockout mouse model cha

260 /vegetable glycerin aerosols increased ACE2 (angiotensin converting enzyme 2) levels, the SARS-CoV-2

261 Since angiotensin-converting enzyme 2 metabolizes angiotensin

262 inent effects on host proteins, most notably angiotensin-converting enzyme 2, might also provide wort

263 gainst SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both

264 Angiotensin-converting enzyme 2 myocardial expression di

265 tor-binding domain of the spike protein with angiotensin-converting enzyme 2 on the host cell surface

266 2 infection is binding of the virus to ACE2 (angiotensin-converting enzyme 2) on the airway epitheliu

267 h other respiratory viruses that do not bind angiotensin-converting enzyme-2 (p < 0.001) experienced

268 nts with other respiratory viruses that bind angiotensin-converting enzyme-2 (p = 0.061) and 12% (95%

269 Angiotensin-converting enzyme 2 pseudo-neutralization on

270 Heavily glycosylated S trimers bind to the angiotensin-converting enzyme 2 receptor and mediate ent

271 s the interplay between virus binding to the angiotensin-converting enzyme 2 receptor and the impact

272 capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike p

273 oV-2 spike glycoprotein (S protein) and host angiotensin-converting enzyme 2 receptor following mutat

274 f its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and air

275 the respiratory tract, the expression of the angiotensin-converting enzyme 2 receptor in other tissue

276 quilibrium constant for binding to the human angiotensin-converting enzyme 2 receptor more than 3.5-f

277 viral spike protein subunit 1 and the human angiotensin-converting enzyme 2 receptor protein.

278 l, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important r

279 18 of 69 (26.1%) of individuals did not have angiotensin-converting enzyme 2 receptor-blocking Abs, w

280 main and prevents interaction with the human angiotensin-converting enzyme 2 receptor.

281 ronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor.

282 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor.

283 nalysis demonstrates that it binds the human angiotensin-converting enzyme-2 receptor with a 4-fold h

284 etails of prefusion spike protein binding to angiotensin-converting enzyme 2 remain elusive at the mo

285 izing the protease activity of its receptor, angiotensin-converting enzyme 2, S protein induces an in

286 ght to determine whether circulating soluble angiotensin-converting enzyme 2 (sACE2) is increased in

287 ally, NETs triggered by SARS-CoV-2 depend on angiotensin-converting enzyme 2, serine protease, virus

288 Although angiotensin-converting enzyme 2 serves as the portal for

289 renin-angiotensin system and is a homolog of angiotensin-converting enzyme 2, sharing approximately 5

290 ke protein trimer immunoglobulin G inhibited angiotensin-converting enzyme 2-spike protein binding to

291 mAbs significantly blocked RBD-Fc binding to angiotensin-converting enzyme 2, suggesting that their e

292 Expression of mRNA for angiotensin converting enzyme 2, the SARS-CoV receptor,

293 omain (RBD), which mediates virus binding to angiotensin-converting enzyme 2, the functional receptor

294 dicate that endothelial cells do not express angiotensin-converting enzyme 2, the receptor that SARS-

295 onsists of angiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin

296 n culture, and conferred protection in human angiotensin-converting enzyme 2-transgenic (ACE2-transge

297 Recently, angiotensin converting enzyme 2 was identified as a prim

298 Angiotensin-converting enzyme 2 was rarely expressed, wh

299 Recently, recombinant angiotensin-converting enzyme 2 was shown to protect mic

300 CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on